Cmax is out of the range [Study As­sess­ment]

posted by Mikalai  – Belarus, 2018-08-01 12:05 (991 d 12:44 ago) – Posting: # 19121
Views: 3,514

Dear all,
We recently conducted a BE trial. It was a classical 2-period, 2-sequence study of a drug that consists of a combination of two active substances. Unfortunately, results one of analytes, a parent drug, fell sightly outside of the 80-125% range, below 80% for Cmax. CV was below 30% and post-hoc power was less than 80% for this analyte. Are there any ways we can defend bioequivalence without conducting another BE trail? All other analytes fell within 80-125%. Specifically, what should we put in the protocol or in a supporting letter to justify our lower border of CI around 79% for Cmax?

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 7 (0 registered, 7 guests [including 1 identified bots]).
Forum time: Monday 00:50 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz